More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Emerging pharma companies play an important role in new product development. Which companies are making strong plays based on recent high-value partnering deals? DCAT Value Chain Insights' Top 10 highlights the rising players. Emerging pharma...

The biopharma industry, both biopharmaceutical/pharmaceutical companies and CDMOs/CMOS, has been a target of increased investment by private-equity (PE) firms. A recent analysis by Bain & Company examines financing trends and investments by PE...

Driven by growth in oncology drugs, high-potency manufacturing is an active area of investment by CDMOs/CMOs. Which CDMOs/CMOs are making investments? DCAT Value Chain Insights rounds up key recent expansions for drug substances and drug...

Immunotherapies represent a growing sector in the global oncology pharmaceutical market. Now led by Merck & Co.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), immunotherapies by Roche and AstraZeneca are joining the...

As lockdown measures to COVID-19 are slowly being lifted globally, how are companies responding? A recent PwC survey of nearly 870 CFOs in 24 territories examines companies' plans with respect to supply chains, sourcing, capital expenditures,...

Following AbbVie's $63-billion acquisition of Allergan, which closed earlier this month (May 2020), the new AbbVie, reflecting the combined companies, has projected revenues of $50 billion. DCAT Value Chain Insights examines the key products, both...